{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:01:30Z","timestamp":1787806890129,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ygyno.2018.07.017","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T18:37:37Z","timestamp":1533580657000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer"],"prefix":"10.1016","volume":"151","author":[{"given":"Kathleen N.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 10","key":"10.1016\/j.ygyno.2018.07.017_bb0005","doi-asserted-by":"crossref","first-page":"x118","DOI":"10.1093\/annonc\/mds315","article-title":"Optimal first-line treatment in ovarian cancer","volume":"23","author":"Raja","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0010","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian Cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2015.11.005","article-title":"A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer","volume":"140","author":"Bouchard-Fortier","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5732\/cjc.014.10274","article-title":"Ovarian cancer standard of care: are there real alternatives?","volume":"34","author":"Della Pepa","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0035","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0040","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0045","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0050","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0055","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0060","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0065","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0070","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0075","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0080","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","article-title":"Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy","volume":"56","author":"Elnakat","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0085","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-014-9539-8","article-title":"Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications","volume":"34","author":"Vergote","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V","article-title":"Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer","volume":"79","author":"Toffoli","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0100","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/OTT.S40947","article-title":"Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review","volume":"7","author":"Marchetti","year":"2014","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted cancer therapy: conferring specificity to cytotoxic drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0110","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1358\/dof.2016.041.09.2544475","article-title":"Mirvetuximab soravtansine. FRa-targeting ADC; treatment of epithelial ovarian cancer","volume":"41","author":"Gunderson","year":"2016","journal-title":"Drugs Future"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0120","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1158\/1535-7163.MCT-10-0645","article-title":"Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability","volume":"9","author":"Oroudjev","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117523","article-title":"High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction","volume":"10","author":"Goldmacher","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0130","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","article-title":"Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen","volume":"66","author":"Kovtun","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0135","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","article-title":"Mirvetuximab Soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models","volume":"18","author":"Ponte","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0145","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0150","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0160","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0165","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0170","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-018-3532-9","article-title":"PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer","volume":"81","author":"Morgan","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0175","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx450","article-title":"Front-line therapy of advanced epithelial ovarian cancer: standard treatment","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0180","article-title":"Antibody-drug conjugates for cancer therapy","volume":"4","author":"Parslow","year":"2016","journal-title":"Biomedicine"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0185","article-title":"FORWARD I: a phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0190","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0195","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdr441","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","volume":"23","author":"Gladieff","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2007.08.092","article-title":"Clinical trial endpoints in ovarian cancer: report of an FDA\/ASCO\/AACR public workshop","volume":"107","author":"Bast","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0205","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.017_bb0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2013.11.008","article-title":"Ovarian cancer clinical trial endpoints: society of gynecologic oncology white paper","volume":"132","author":"Herzog","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.017_bb0215","volume":"35","author":"O'Malley","year":"2017","journal-title":"J Clin Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818310813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818310813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T13:13:56Z","timestamp":1540473236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818310813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0090825818310813"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}